| A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance A Alkrekshi, W Wang, PS Rana, V Markovic, K Sossey-Alaoui Cellular signalling 85, 110073, 2021 | 44 | 2021 |
| Immune checkpoint inhibitor-related pulmonary toxicity: focus on nivolumab H Bukamur, H Katz, M Alsharedi, A Alkrekshi, YR Shweihat, NJ Munn Southern medical journal 113 (11), 600, 2020 | 36 | 2020 |
| The role of WAVE2 signaling in cancer PS Rana, A Alkrekshi, W Wang, V Markovic, K Sossey-Alaoui Biomedicines 9 (9), 1217, 2021 | 16 | 2021 |
| Safety of immune checkpoint inhibitors in patients with cancer and hepatitis C virus infection A Alkrekshi, I Tamaskar The oncologist 26 (5), e827-e830, 2021 | 15 | 2021 |
| Temporal trends in craniopharyngioma management and long‐term endocrine outcomes: A multicentre cross‐sectional study Z Hussein, N Glynn, N Martin, A Alkrekshi, N Mendoza, R Nair, ... Clinical Endocrinology 94 (2), 242-249, 2021 | 11 | 2021 |
| Targeted deletion of kindlin-2 in mouse mammary glands inhibits tumor growth, invasion, and metastasis downstream of a TGF-β/EGF oncogenic signaling pathway W Wang, PS Rana, A Alkrekshi, K Bialkowska, V Markovic, ... Cancers 14 (3), 639, 2022 | 7 | 2022 |
| YB1 is a major contributor to health disparities in triple negative breast cancer PS Rana, W Wang, A Alkrekshi, V Markovic, A Khiyami, R Chan, ... Cancers 13 (24), 6262, 2021 | 6 | 2021 |
| Risk of non-hodgkin's lymphoma in HCV patients in the united states between 2013 and 2020: A population-based study A Alkrekshi, A Kassem, C Park, W Tse Clinical Lymphoma Myeloma and Leukemia 21 (11), e832-e838, 2021 | 6 | 2021 |
| Grade III solitary fibrous tumor/hemangiopericytoma: An enthralling intracranial tumor—A case report and literature review AR Al Armashi, A Alkrekshi, A Al Zubaidi, FJ Somoza-Cano, F Hammad, ... Radiology Case Reports 17 (10), 3792-3796, 2022 | 4 | 2022 |
| Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data J Wang, S Dasari, D Elantably, A Alkrekshi, YD Kim Acta Oncologica 61 (9), 1157-1161, 2022 | 4 | 2022 |
| Immune checkpoint inhibitor-related pulmonary toxicity: a comprehensive review, part II H Bukamur, A Alkrekshi, H Katz, M Alsharedi, YR Shweihat, NJ Munn Southern Medical Journal 114 (9), 614, 2021 | 4 | 2021 |
| CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study J Wang, A Alkrekshi, S Dasari, HTC Lin, D Elantably, ARA Armashi Bone Marrow Transplantation 58 (11), 1223-1228, 2023 | 3 | 2023 |
| Abstract P1-06-02: Targeted deletion of Kindlin-2 in mouse mammary glands inhibits tumor growth, invasion and metastasis downstream of TGF-β/EGF oncogenic signaling pathway P Rana, W Wang, A Alkrekshi, K Bialkowska, V Markovic, EF Plow, ... Cancer Research 82 (4_Supplement), P1-06-02-P1-06-02, 2022 | 2 | 2022 |
| Trends and survival of malignant mesothelioma across racial groups between 2000-2019: A real-world study. AR Al Armashi, A Alkrekshi, A Al Zubaidi, F Hammad, D Elantably, ... Journal of Clinical Oncology 41 (16_suppl), e20539-e20539, 2023 | 1 | 2023 |
| The risk of stroke and myocardial infarction in multiple myeloma: a population-based study in the United States AR Al Armashi, D Elantably, J Wang, A Al Zubaidi, A Alkrekshi Blood 140 (Supplement 1), 7226-7227, 2022 | 1 | 2022 |
| S54 Trends in Race-Specific Mortality From Pancreatic Cancer in the United States Between 2000 and 2020 A Al Zubaidi, AR Al Armashi, F Hammad, AK Chandar, M Homeida, ... Official journal of the American College of Gastroenterology| ACG 117 (10S), e41, 2022 | 1 | 2022 |
| Shewanella septic shock complicating COVID-19 survivorship following extracorporeal membrane oxygenation (ECMO) recovery SC Potla, Z Zia, A Alkrekshi, R Kalayjian, I Kourouni Chest 162 (4), A465, 2022 | 1 | 2022 |
| Iatrogenic esophageal and tracheal perforation with tracheoesophageal fistula following emergency intubation A Alkrekshi, H Bukamur Clinical Case Reports, 2020 | 1 | 2020 |
| YB1 is a novel therapeutic for the treatment of triple negative breast cancer tumors W Wang, LE Khalki, NY Zai, J Szpendyk, A Alkrekshi, B Su, ... Cancer Research 84 (6_Supplement), 5728-5728, 2024 | | 2024 |
| Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020 AR Al Armashi, A Al Zubaidi, O Mahmood, M Thierheimer, A Alkrekshi, ... Blood 142, 1765, 2023 | | 2023 |
